Novartis

Novartis
2012 Vaccine revenue: $1.38 billion


For a few months back in 2012, the future of Novartis' ($NVS) vaccine unit seemed to hang in the balance. The company needed an approval of its meningitis B vaccine to make the $7.5 billion buyout of Chiron and its vaccine candidates in 2006 stand for something. An EU approval of Bexsero in January allowed the executives at Novartis to breathe a sigh of relief. Analysts expect the European market for the shot to settle between $600 million and $700 million. 

While Novartis' vaccine revenues trail those of competitors, it is forecast to have the highest growth rate through 2018 tied to anticipated sales of Bexsero and Menveo, also a meningococcal meningitis vaccine. The company's vaccine revenue hit $1.4 billion in 2012 and will likely rise to $3.14 billion by 2018, more than twice what it is today.

For more:
Novartis lands EU approval of meningitis B vaccine Bexsero
Novartis rides high on Bexsero study results
Novartis vaccines unit's future hangs on Bexsero approval
Novartis vaccine Bexsero combats meningitis

-- Alison Bryant

Novartis
Read more on

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.